Improvement in patient-reported outcomes after rituximab in rheumatoid arthritis patients: An open-label assessment of 175 patients - Université Paris Cité Accéder directement au contenu
Article Dans Une Revue Joint Bone Spine Année : 2015

Improvement in patient-reported outcomes after rituximab in rheumatoid arthritis patients: An open-label assessment of 175 patients

Résumé

Objective : Patient-reported outcomes (PROs) reflect treatment efficacy from the patients’ perspective. The objective was to assess PROs improvement with rituximab in rheumatoid arthritis. Methods : Patients with long-standing rheumatoid arthritis received rituximab 1000 mg twice at 2 weeks interval, and were assessed over 6 months. PROs including physical PROs (pain, functional assessment, physical quality of life) and mental or mixed aspects (fatigue, sleep and mental quality of life) were assessed. Standardized response means were calculated. Early improvement in PROs was used to predict EULAR response at 6 months. Results : For the 175 patients (mean age 54.6 ± 10.6 years, mean disease duration 12.9 ± 9.3 years), the plateau of efficacy of rituximab on PROs was reached at week 12, and the effect was more prominent on physical PROs (e.g., pain standardized response means −0.75 [95% confidence interval −0.91; −0.60]), than on sleep (−0.43; [−0.56; −0.29]). It was not possible to accurately predict 6-month EULAR response by early improvement in PROs. Conclusion : Rituximab was effective on PROs with an early effect. PROs reflecting physical aspects were more modulated by this biologic than other PROs (fatigue, sleep or mental quality of life). Links between sleep difficulties, fatigue and RA should be further studied.
Fichier principal
Vignette du fichier
Gossec_Improvement_in.pdf (174.18 Ko) Télécharger le fichier
Origine : Fichiers produits par l'(les) auteur(s)
Loading...

Dates et versions

hal-01189082 , version 1 (01-09-2015)

Identifiants

Citer

Laure Gossec, Agnès Danré, Bernard Combe, Xavier Le Loët, Jaques Tebib, et al.. Improvement in patient-reported outcomes after rituximab in rheumatoid arthritis patients: An open-label assessment of 175 patients. Joint Bone Spine, 2015, 82 (6), pp.451-454. ⟨10.1016/j.jbspin.2015.02.007⟩. ⟨hal-01189082⟩
143 Consultations
265 Téléchargements

Altmetric

Partager

Gmail Facebook X LinkedIn More